Table 2.

SET_ER/PR for prediction of progression-free survival

	HR	95 % CI	p
Chemotherapy (N = 33)
SETER/PR	0.935	0.426−2.053	0.868
Endocrine treatment (N = 97)
SETER/PR	0.420	0.273−0.644	<0.001
Endocrine treatment and relapsed stage IV (N = 79)
SETER/PR	0.407	0.253−0.654	<0.001
Endocrine treatment and relapsed stage IV
SETER/PR	0.534	0.299−0.955	0.035
PR status	0.604	0.335−1.087	0.093
Visc. met.	1.502	0.851−2.653	0.161
Event >2	2.904	1.457−5.788	0.002
Prior Sens.	0.466	0.246−0.884	0.019
Endocrine treatment and relapsed stage IV and prior sensitivity (N = 46)
SETER/PR	0.287	0.147−0.561	<0.001
Endocrine treatment and relapsed stage IV and prior sensitivity
SETER/PR	0.303	0.143−0.642	0.002
PR status	0.497	0.249−0.992	0.047
Visc. met.	1.063	0.509−2.220	0.871
Event >2	3.779	1.699−8.407	0.001

Cox regression analyses for prediction of progression-free survival using the dichotomized SET_ER/PR. Results are shown for patients that received chemotherapy and those that received endocrine treatment. Uni- and multivariate analyses are shown for the clinically relevant subgroups of patients that received endocrine treatment and presented with relapsed stage IV disease and the subset of patients with a prior history of endocrine sensitivity

HR hazard ratio, CI confidence interval